AMPH
Amphastar P
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 885.13M; Volume: 32.26K; AvgVol 3m: 224.72K; Beta: 0.98;
Cost estimate:
P/E: 227.22; EPS: 0.08; EPS growth quarter/prev quarter: -100.40%;
EPS growth this year: 892.90%; EPS growth past 5 years: 42.40%;
EPS ttm: 0.08;
P/S: 2.88; P/B: 2.37; P/Cashflow: 9.76; P/FCF: ;
Sales: 334.02M; Sales growth quarter/prev quarter: 8.60%; Sales growth past 5 years: 8.90%;
Profitability:
Gross Margin: 41.50%; Profit Margin: 1.20%; Operating Margin: 2.00%;
ROA – return on assets: 0.70%; ROE – return on equity: 1.00%; LT Debt/Equity: 0.09; Total Debt/Equity: 0.12;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.70%; Insider Transactions:-27.39%;
Institutional Ownership: 56.30%; Institutional Transactions: 8.66%;
Data update: 07/10/2020.